SCHEMBL6709643

SCHEMBL6709643

O=C(c1ccc(Cl)s1)N1CCN(c2ccc(NCc3cccnc3CC3CCCCC3)cc2)CC1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.48
GFER P55789 2/20 0.40
ALDH1A1 P00352 6/20 0.39
HPGD P15428 1/20 0.39
LMNA P02545 2/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
GAA P10253 3/20 0.38
ALOX15 P16050 3/20 0.38
ALOX12 P18054 3/20 0.38
MAPK1 P28482 1/20 0.38
KDM4E B2RXH2 4/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
SLC6A7 Q99884 2/20 0.37
THRB P10828 1/20 0.37
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6715237 0.76 MAPT (0.56) MAPTGFERALDH1A1LMNAHTT
SCHEMBL6709607 0.70 MAPT (0.54) MAPTGFERALDH1A1HPGDLMNA
SCHEMBL6709641 0.69 MAPT (0.48) MAPTALDH1A1HPGDLMNAHTT
SCHEMBL6709632 0.69 MAPT (0.48) MAPTGFERALDH1A1HPGDLMNA
SCHEMBL6710873 0.69 SMN1; SMN2 (0.62) MAPTGFERALDH1A1HPGDLMNA
SCHEMBL6715174 0.69 MAPT (0.54) MAPTGFERALDH1A1HPGDLMNA
SCHEMBL6711133 0.66 MAPT (0.55) MAPTALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL6709685 0.66 MAPT (0.75) MAPTGFERALDH1A1HPGDLMNA
SCHEMBL6710804 0.65 FNTA (0.47)
SCHEMBL6983035 0.65 MAPT (0.43) MAPTALDH1A1LMNAHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092524-A1 Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and method for preparing same PIERRE FABRE MEDICAMENT (FR) 2004-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092524-A1 Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and method for preparing same CBR3, CBR1, HCCS MAPT 4753/4885GFER 1790/4885ALDH1A1 3031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.